Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISM study of nalbuphine extended-release tablets in prurigo nodularis
2018-001219-53Phase 2Completed
- Sponsor
- Trevi Therapeutics
- Start
- Jul 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prurigo nodularis (PN) comparing Nalbuphine ER with Placebo (2 arms). Primary endpoint: Week 14 WI-NRS responder rate. Started Jul 2018; status: completed.
02
Drugs
nalbuphine
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on 2018-001219-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001219-53.